2026-06-14T00:29:42Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/89802025-05-07T09:12:02Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_19609col_20.500.12105_16968

00925njm 22002777a 4500 dc Kissling, Esther author Rose, Angela Mc author Emborg, Hanne-Dorthe author Gherasim, Alin Manuel author Pebody, Richard author Pozo Sanchez, Francisco author Trebbien, Ramona author Mazagatos, Clara author Whitaker, Heather author Valenciano, Marta author European IVE group author Larrauri, Amparo author Casas Flecha, Inmaculada author Delgado-Sanz, Concepcion author Oliva Dominguez, Jesus Angel author 2019 Influenza A(H1N1)pdm09 and A(H3N2) viruses both circulated in Europe in October 2018-January 2019. Interim results from six studies indicate that 2018/19 influenza vaccine effectiveness (VE) estimates among all ages in primary care was 32-43% against influenza A; higher against A(H1N1)pdm09 and lower against A(H3N2). Among hospitalised older adults, VE estimates were 34-38% against influenza A and slightly lower against A(H1N1)pdm09. Influenza vaccination is of continued benefit during the ongoing 2018/19 influenza season. Euro Surveill. 2019 Feb;24(8):1900121. 10.2807/1560-7917.ES.2019.24.1900121 1560-7917 1560-7917 Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 30808440 http://hdl.handle.net/20.500.12105/8980 Europe Influenza Multicentre study Test-negative design Vaccination Vaccine effectiveness Vaccines and immunisation Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019